Kura Oncology Inc. has received full approval from the U.S. Food and Drug Administration for KOMZIFTI™ (ziftomenib), an oral menin inhibitor, for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1 mutation who have no satisfactory alternative treatment options. This approval was supported by data from the KOMET-001 clinical trial and marks KOMZIFTI as the first and only once-daily FDA-approved menin inhibitor for this indication. The therapy has also been added to the National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in Oncology as a Category 2A recommended treatment option.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9592458-en) on November 25, 2025, and is solely responsible for the information contained therein.